Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_assertion type Assertion NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_head.
- NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_assertion description "[Epigenetic inactivation of MIR129-2 was studied by methylation-specific PCR (MSP) in 13 cell lines (eight myeloma and five lymphoma), 15 normal controls and 344 primary samples including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) at diagnosis, MM at relapse/progression, and monoclonal gammopathy of undetermined significance (MGUS).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_provenance.
- NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_assertion evidence source_evidence_literature NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_provenance.
- NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_assertion SIO_000772 23406679 NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_provenance.
- NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_assertion wasDerivedFrom befree-20150227 NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_provenance.
- NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_assertion wasGeneratedBy ECO_0000203 NP993337.RA-tpgteNqCy9VhG6leK6abJH0wHK4V55XlzTnPZ9r8bk130_provenance.